International Journal of Clinical Pharmacy
Fecha de publicación: 20 March 2018
DOI: https://doi.org/10.1007/s11096-018-0621-0
Autores:
Background: HIV–HCV coinfection produces high morbi-mortality. Direct-acting antivirals (DAAs) have shown high efficacy, although special attention should be paid to the risk of drug interactions. However, due to the lack of representativeness of coinfected patients in clinical trials, it is important to know real-world results.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.